Seres Therapeutics Inc. plans to start selling its first FDA-approved product, a drug called Vowst made of bacterial spores derived from donated feces, this summer at $17,500 a course.

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell ...

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 ...

Organizing a successful test event in Ecuador, SERES presents 4 new energy vehicles suitable for the natural environment and user needs of Latin America. CHONGQING, China--(BUSINESS WIRE)--SERES ...